Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) FCF Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:03378 Hanx Biopharmaceuticals (Wuhan) Co Ltd HKSE:03378
11 GF Score
Price HK$27.56
! 1 Warning Sign
View Full Analysis

What is Hanx Biopharmaceuticals (Wuhan) Co FCF Margin %?

Hanx Biopharmaceuticals (Wuhan) Co HKSE:03378 +6.00% 11 FCF Margin % is 0.00% as of Dec. 2025. GuruFocus rates HKSE:03378 with a GF Score™ of 11/100. The stock has 1 warning sign investors should review. Among 952 Biotechnology companies, Hanx Biopharmaceuticals (Wuhan) Co ranks worse than 105041.91% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Hanx Biopharmaceuticals (Wuhan) Co's Free Cash Flow for the six months ended in Dec. 2025 was HK$-115.25 Mil. Hanx Biopharmaceuticals (Wuhan) Co's Revenue for the six months ended in Dec. 2025 was HK$0.00 Mil. Therefore, Hanx Biopharmaceuticals (Wuhan) Co's FCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Hanx Biopharmaceuticals (Wuhan) Co's current FCF Yield % is -3.12%.

The historical rank and industry rank for Hanx Biopharmaceuticals (Wuhan) Co's FCF Margin % or its related term are showing as below:


HKSE:03378's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -82.715
* Ranked among companies with meaningful FCF Margin % only.


Hanx Biopharmaceuticals (Wuhan) Co FCF Margin % Related Terms


Hanx Biopharmaceuticals (Wuhan) Co FCF Margin % Historical Data

* Premium members only.

The historical data trend for Hanx Biopharmaceuticals (Wuhan) Co's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hanx Biopharmaceuticals (Wuhan) Co FCF Margin % Chart

Hanx Biopharmaceuticals (Wuhan) Co Annual Data
Trend Dec23 Dec24 Dec25
FCF Margin %
0.00 0.00 0.00

Hanx Biopharmaceuticals (Wuhan) Co Semi-Annual Data
Dec23 Dec24 Dec25
FCF Margin % 0.00 0.00 0.00

HKSE:03378 vs VRTX, REGN, RVMD: FCF Margin % Comparison

For the Biotechnology subindustry, Hanx Biopharmaceuticals (Wuhan) Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hanx Biopharmaceuticals (Wuhan) Co FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hanx Biopharmaceuticals (Wuhan) Co's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Hanx Biopharmaceuticals (Wuhan) Co's FCF Margin % falls into.


HKSE:03378
11GF Score
Hanx Biopharmaceuticals (Wuhan) Co Ltd HKSE:03378
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hanx Biopharmaceuticals (Wuhan) Co FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Hanx Biopharmaceuticals (Wuhan) Co's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-115.247/0
= %

Hanx Biopharmaceuticals (Wuhan) Co's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-115.247/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) has a FCF Margin % of 0.00% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Hanx Biopharmaceuticals (Wuhan) Co and its competitors. According to the industry distribution chart, Hanx Biopharmaceuticals (Wuhan) Co ranks #999999 out of 952 companies in the Biotechnology industry.
Is Hanx Biopharmaceuticals (Wuhan) Co's FCF Margin % too high?
Hanx Biopharmaceuticals (Wuhan) Co's current FCF Margin % is 0.00%. Based on the distribution chart, Hanx Biopharmaceuticals (Wuhan) Co ranks #999999 out of 952 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Hanx Biopharmaceuticals (Wuhan) Co has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hanx Biopharmaceuticals (Wuhan) Co's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hanx Biopharmaceuticals (Wuhan) Co ranks #999999 out of 952 companies for FCF Margin %. This places Hanx Biopharmaceuticals (Wuhan) Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Hanx Biopharmaceuticals (Wuhan) Co and its competitors. Hanx Biopharmaceuticals (Wuhan) Co's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hanx Biopharmaceuticals (Wuhan) Co stock overvalued right now?
Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Hanx Biopharmaceuticals (Wuhan) Co's overall GF Score™ is 11/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Hanx Biopharmaceuticals (Wuhan) Co (HKSE:03378), the current FCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hanx Biopharmaceuticals (Wuhan) Co Business Description

Address No. 1 Jiufeng 1st Road, Building A8, Phase II, Bio-Innovation Park, East Lake New Technology Development Zone, Hubei, Wuhan, CHN
Hanx Biopharmaceuticals (Wuhan) Co Ltd is a biotech company with in-house capabilities in structural biology, translational medicine, and clinical development, focused on developing immunotherapeutic products. Its product pipeline comprises one Core Product and nine other pipeline candidates: three clinical-stage drug candidates focused on oncology, including its Core Product HX009 and Key Products HX301 and HX044; and seven preclinical-stage drug candidates, including an antibody drug conjugate, a bispecific antibody, and a monoclonal antibody for both autoimmune and oncology markets.
11GF Score

Get the complete analysis for HKSE:03378

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$27.56
Price